PMID- 28277841
OWN - NLM
STAT- MEDLINE
DCOM- 20170404
LR  - 20170404
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 16
IP  - 4
DP  - 2017 Apr
TI  - Safety of tocilizumab in the treatment of juvenile idiopathic arthritis.
PG  - 493-500
LID - 10.1080/14740338.2017.1303479 [doi]
AB  - Tocilizumab (TCZ) is a recombinant humanized monoclonal antibody and IL-6 
      receptor antagonist, currently approved for the treatment of systemic juvenile 
      idiopathic arthritis (sJIA) and polyarticular juvenile idiopathic arthritis 
      (pJIA) in children aged 2 years or older refractory to conventional treatment. 
      The most common adverse events in patients treated with TCZ were infections, 
      especially in the respiratory tract. The most frequent laboratory abnormalities 
      were altered liver function, neutropenia and elevated cholesterol levels. Areas 
      covered: The safety of TCZ in the treatment of children with JIA was determined 
      based on a review of published clinical trials, including two multicenter studies 
      of patients with sJIA and pJIA (the TENDER and CHERISH trials, respectively). The 
      frequency of adverse events (AEs), serious adverse events (SAEs) and deaths 
      reported in these studies was analyzed and discussed. Expert opinion: TCZ was 
      effective and well tolerated in the treatment of severe forms of sJIA and pJIA, 
      and can be considered a treatment of choice for these conditions. The risk of 
      infections and laboratory abnormalities, such as neutropenia, should be 
      constantly monitored. There is still a need for comparative studies of the risks 
      and benefits of biological agents in patients with refractory JIA.
FAU - Machado, Sandra Helena
AU  - Machado SH
AD  - a Department of Internal Medicine , Universidade Federal do Rio Grande do Sul 
      (UFRGS), Hospital de Clinicas de Porto Alegre (HCPA) , Porto Alegre , Brazil.
FAU - Xavier, Ricardo Machado
AU  - Xavier RM
AD  - b Rheumatology Service , Hospital de Clinicas de Porto Alegre (HCPA) , Porto 
      Alegre , Brazil.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Receptors, Interleukin-6)
RN  - I031V2H011 (tocilizumab)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized/adverse effects/pharmacology/*therapeutic use
MH  - Antirheumatic Agents/adverse effects/pharmacology/*therapeutic use
MH  - Arthritis, Juvenile/*drug therapy/physiopathology
MH  - Child
MH  - Child, Preschool
MH  - Humans
MH  - Receptors, Interleukin-6/antagonists & inhibitors
MH  - Respiratory Tract Infections/chemically induced/epidemiology
MH  - Severity of Illness Index
OTO - NOTNLM
OT  - IL-6 inhibitors
OT  - juvenile idiopathic arthritis
OT  - safety
OT  - treatment
EDAT- 2017/03/10 06:00
MHDA- 2017/04/05 06:00
CRDT- 2017/03/10 06:00
PHST- 2017/03/10 06:00 [pubmed]
PHST- 2017/04/05 06:00 [medline]
PHST- 2017/03/10 06:00 [entrez]
AID - 10.1080/14740338.2017.1303479 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2017 Apr;16(4):493-500. doi: 10.1080/14740338.2017.1303479.